An interview with vice president of pharmaceutical trade relations for Accredo Rob Osborne.
Rob Osborne
$16 billion dollars. That’s the projected cost of gene therapies in 2024, according to EvaluatePharma, a London-based firm that provides commercial intelligence for the life science industry.
“The cost of many medications has a significant impact on the budgets of employers and insurers and can become unsustainable for health plans, patients, and their families,” says Rob Osborne, vice president of pharmaceutical trade relations for Accredo, a specialty pharmaceutical provider, and CuraScript SD, a pharmaceutical distributor, both of which are part of the Express Scripts family of companies.
The consequence of not figuring this out for payers, providers, and patients? High costs and unpredictability-both of which create tough coverage decisions for employers and health plans, says Osborne, who will speak at the Pharmaceutical Care Management Association Annual Meeting, which takes place in Scottsdale, Arizona, on September 23 and 24.
To address the challenge of getting these costly and lifesaving therapies to patients, he asks pharmaceutical leaders to channel their innovation-the very same innovation they tapped to bring lifesaving therapies to the marketplace-into figuring out how to make them accessible and affordable to patients and families.
Managed Healthcare Executive (MHE) recently talked to Osborne about the need for new payment and contracting models for specialty drugs. The conversation was lightly edited for clarity.
Related: Combatting Pharma Prices with a High-Touch Pharmacy Service Model
MHE: What’s your overall strategy regarding new payment and contracting models for these new treatments?
Osborne: Express Scripts, which is part of Cigna, is a health services company that helps employers and health plans make medications safer, more accessible, and more affordable for more than 100 million Americans. We want to offer the marketplace new payment and contracting models that are simple, affordable, and predictable.
For more than 30 years, Express Scripts has stood alongside our clients, improving their members’ access to medications by inventing cost-saving solutions that provide great care to patients. We’re committed to looking for ways to expand access to innovative medications through solutions that improve quality and affordability.
MHE: Tell me about concrete efforts you’ve made to increase access to gene therapies.
Osborne: Gene therapies are one-time use drugs, and sometimes they’re curative. They’re innovative and can be very effective, but they’re expensive.
Embarc Benefit Protection, our most recent initiative, provides predictability for payers [to manage] the shock of a gene therapy claim through a fixed-dollar amount, per-person payment. This solution may insulate payers from the unpredictable “lightning strike” of high-cost gene therapy drug expenses, and thus make exclusion of coverage less likely.
An innovative payment model that Accredo is offering to payers is the ability to pay for these one-time therapies over time. Over a pre-determined payment schedule, health insurers can pay for these high-cost therapies over a number of years. This solution may help payers with their budgets and offer predictability in order to potentially make exclusion coverage less likely.
Aine Cryts is a writer based in Boston.
Emerging Therapies Committee at UC Davis Hits the Accelerator Not the Brake | AMCP 2024
April 18th 2024After the onboarding of cell and gene therapy bogged using normal pharmacy and therapeutics (P&T) committee procedures, UC Davis Health set up an emerging therapeutics committee to streamline and speed up the process of delivery expensive cell and gene therapies.
Read More
DC Roundtable: Patrick Cooney of The Federal Group Drops the Latest on PBM Legislation in Washington
April 11th 2024In this episode of "DC Roundtable," Peter Wehrwein, managing editor of Managed Healthcare Executive, spoke with Patrick Cooney, president of The Federal Group, a lobbying and strategic planning firm in Washington, D.C., about recent developments in Washington concerning PBMs.
Listen
2024 Emerging Leaders in Healthcare — Submit For a Chance to Be Featured in MHE's August Issue
April 18th 2024MHE Editors are seeking diverse healthcare professionals from different backgrounds and healthcare sectors, with individual interests. Eligible candidates are early or mid-career leaders with less than 10 years of experience. Award winners will enjoy complimentary passes to the PBMI Annual National Meeting in Orlando, Florida, from Sept. 4-6. Additional perks include a feature in our August issue, a subscription to MHE and more!
Read More